Melatonin synergizes BRAF‐targeting agent dabrafenib for the treatment of anaplastic thyroid cancer by inhibiting AKT/hTERT signalling

As a selective inhibitor of BRAF kinase, dabrafenib has shown potent anti‐tumour activities in patients with BRAFV600E mutant anaplastic thyroid cancer. However, the resistance of thyroid cancer cells to dabrafenib limited its therapeutic effect. The effects of melatonin and dabrafenib as monotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Yina, Gao, Yao, Chang, An, Li, Zongjuan, Wang, Huayu, Cao, Jing, Gu, Wei, Tang, Ranran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7579709/
https://www.ncbi.nlm.nih.gov/pubmed/32935463
http://dx.doi.org/10.1111/jcmm.15854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7579709/
https://www.ncbi.nlm.nih.gov/pubmed/32935463
http://dx.doi.org/10.1111/jcmm.15854

Ejemplares similares